Perspective Therapeutics, Inc. (CATX)
XASE:CATX
Want to see CATX full AI Analyst Report?
CATX Stock Chart & Stats
$4.20
-$0.13(-3.36%)
At close: 4:00 PM EST
$4.20
-$0.13(-3.36%)
Day’s Range― - ―
52-Week Range$1.96 - $6.16
Previous CloseN/A
Volume311.62K
Average Volume (3M)1.43M
Market Cap
$406.00M
Enterprise Value$253.01M
Total Cash (Recent Filing)$270.93M
Total Debt (Recent Filing)$2.62M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Aug 18, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.41
Shares Outstanding114,046,196
10 Day Avg. Volume1,160,106
30 Day Avg. Volume1,425,090
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio-2.13
Enterprise Value/Market Cap0.62
Enterprise Value/Revenue440.02
Enterprise Value/Gross Profit-122.88
Enterprise Value/Ebitda-2.29
Forecast
1Y Price Target
$12.82Price Target Upside205.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-1.11
Revenue Forecast (FY)$389.33K
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet, Low LeverageVery low leverage and a large equity base provide durable financial flexibility to fund multi-year clinical programs and manufacturing scale-up without immediate refinancing. This reduces short-term solvency risk and allows management to time partnerships or capital raises from a position of strength over the next 2–6 months.
Vertically Integrated Manufacturing And IPOwning the 212Pb supply chain, proprietary chelators and regional manufacturing facilities builds structural competitive advantages: supply reliability, potential margin capture, and higher barriers to entry. This supports sustainable commercialization logistics and partner leverage as programs advance toward registration.
Encouraging Interim Clinical Data Across ProgramsConsistent safety and early efficacy across multiple 212Pb-based assets materially de-risks the platform versus a single-asset profile. Durable signals and tolerability support potential registration discussions, bolster partner interest, and increase the likelihood of later-stage trials that underpin long-term commercial prospects.
Bears Say
High Cash Burn And Negative Cash FlowSustained negative operating and free cash flow imply the company will need additional financing to execute trials and commercial build-out. Persistent cash burn elevates dilution and refinancing risk and could force slower program advancement or scaled-back manufacturing investments absent partner deals or capital raises.
Minimal Commercial Revenue; Large Recurring LossesBeing clinical-stage, the firm lacks recurring product revenues and posts substantial net losses, meaning operating activities do not self-fund. Over the medium term this drives dependence on external capital or licensing, and delays in commercialization keep profitability and margin sustainability uncertain.
Execution And Trial-outcome Risk Remains MaterialClinical progress and manufacturing build-out underpin value but are binary and time-consuming. Trial failures, regulatory setbacks or manufacturing delays would materially impair commercialization timelines and revenue forecasts, making the company's fundamentals contingent on successful execution across multiple complex fronts.
Perspective Therapeutics News
CATX FAQ
What was Perspective Therapeutics, Inc.’s price range in the past 12 months?
Perspective Therapeutics, Inc. lowest stock price was $1.96 and its highest was $6.16 in the past 12 months.
What is Perspective Therapeutics, Inc.’s market cap?
Perspective Therapeutics, Inc.’s market cap is $406.00M.
When is Perspective Therapeutics, Inc.’s upcoming earnings report date?
Perspective Therapeutics, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 74 days.
How were Perspective Therapeutics, Inc.’s earnings last quarter?
Perspective Therapeutics, Inc. released its earnings results on May 11, 2026. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.294 by $0.044.
Is Perspective Therapeutics, Inc. overvalued?
According to Wall Street analysts Perspective Therapeutics, Inc.’s price is currently Undervalued.
Does Perspective Therapeutics, Inc. pay dividends?
Perspective Therapeutics, Inc. does not currently pay dividends.
What is Perspective Therapeutics, Inc.’s EPS estimate?
Perspective Therapeutics, Inc.’s EPS estimate is -0.26.
How many shares outstanding does Perspective Therapeutics, Inc. have?
Perspective Therapeutics, Inc. has 114,046,196 shares outstanding.
What happened to Perspective Therapeutics, Inc.’s price movement after its last earnings report?
Perspective Therapeutics, Inc. reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.294. Following the earnings report the stock price went down -2.835%.
Which hedge fund is a major shareholder of Perspective Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CATX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Perspective Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.82 (205.19% Upside)
$12.82 (205.19% Upside)
Blogger Sentiment
Bullish
CATX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 80.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 6.7%
Last 30 Days ▲ 6.7%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.83%
12-Months-Change
Fundamentals
Return on Equity
-41.84%
Trailing 12-Months
Asset Growth
24.72%
Trailing 12-Months
Company Description
Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
CATX Stock 12 Month Forecast
Average Price Target
$12.82
▲(205.19% Upside)
Technical Analysis
Ownership Overview
1.63% Insiders
7.55% Mutual Funds
35.26% Other Institutional Investors
45.66% Public Companies and
Individual Investors